Soleno: FDA OKs VYKATTM XR to Treat Hyperphagia in Prader-Willi

 First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome

Management to host conference call and webcast today, March 26th, at 5:30pm ET

Patient Support for Accessing VYKAT XR
Today, Soleno has launched Soleno OneTM, a comprehensive patient support program. Information about the program is available at VykatXR.com. The Soleno One team can be reached toll-free at 1-(833)-SOLENO-1 (1-833-765-3661) from 8 a.m. to 8 p.m. ET Monday through Friday. Healthcare providers who want to submit prescriptions can visit VykatXRHCP.com to complete the Start Form that initiates the process for accessing treatment.

Conference Call and Webcast Information
Soleno management will host an investor conference call and webcast with slides to discuss the FDA’s approval of VYKAT XR (diazoxide choline) extended-release tablets today, March 26th, at 5.30pm ET. Details can be found below:

Conference call details:	Toll-free: 1-877-423-9813
	International: 1-201-689-8573
	Conference ID: 13752679
Call me™ (avoids waiting for an operator):	Click here
Webcast:	Click here

A replay of the call will be available following the call on the Investors section of the Soleno website.

https://www.globenewswire.com/news-release/2025/03/26/3050184/0/en/Soleno-Therapeutics-Announces-U-S-FDA-Approval-of-VYKATTM-XR-to-Treat-Hyperphagia-in-Prader-Willi-Syndrome.html